Literature DB >> 17045841

Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells.

Alison H Banham1.   

Abstract

FOXP3+ regulatory T (Treg) cells have crucial roles in maintaining self-tolerance and modulating adaptive immune responses. Functional studies of Treg cells have been hampered by a lack of suitable cell-surface markers that specifically enable their purification without contamination by non-regulatory CD25+ effector T cells. Two recent studies have demonstrated that downregulation of the interleukin-7 receptor (CD127) distinguishes Treg cells from activated T cells, facilitating both Treg-cell purification and their functional characterization in human diseases. CD127 uniquely enables the purification of FOXP3+ Treg cells and, potentially, also "adaptive" regulatory T-cell subsets from the CD4+CD25- T-cell population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17045841     DOI: 10.1016/j.it.2006.10.002

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  42 in total

1.  Phenotypic and functional alterations on inflammatory peripheral blood cells after acute myocardial infarction.

Authors:  Tiago Carvalheiro; Isabel Velada; Ana Valado; Fernando Mendes; António Martinho; Natália António; Lino Gonçalves; Luís Providência; Maria Luísa Pais; Artur Paiva
Journal:  J Cardiovasc Transl Res       Date:  2012-04-21       Impact factor: 4.132

Review 2.  Natural regulatory T cells and persistent viral infection.

Authors:  Shuo Li; Eric J Gowans; Claire Chougnet; Magdalena Plebanski; Ulf Dittmer
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

Review 3.  Functions of γC cytokines in immune homeostasis: current and potential clinical applications.

Authors:  Willem W Overwijk; Kimberly S Schluns
Journal:  Clin Immunol       Date:  2009-05-09       Impact factor: 3.969

4.  Horse versus rabbit antithymocyte globulin in acquired aplastic anemia.

Authors:  Phillip Scheinberg; Olga Nunez; Barbara Weinstein; Priscila Scheinberg; Angélique Biancotto; Colin O Wu; Neal S Young
Journal:  N Engl J Med       Date:  2011-08-04       Impact factor: 91.245

5.  Expression of CD4(+)CD25(high)CD127(low/-) regulatory T cells in transitional cell carcinoma patients and its significance.

Authors:  Xi Zhu; Lin-Lin Ma; Tian Ye
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

6.  Distinct microRNA signatures in human lymphocyte subsets and enforcement of the naive state in CD4+ T cells by the microRNA miR-125b.

Authors:  Riccardo L Rossi; Grazisa Rossetti; Lynn Wenandy; Serena Curti; Anna Ripamonti; Raoul J P Bonnal; Roberto Sciarretta Birolo; Monica Moro; Maria C Crosti; Paola Gruarin; Stefano Maglie; Francesco Marabita; Debora Mascheroni; Valeria Parente; Mario Comelli; Emilio Trabucchi; Raffaele De Francesco; Jens Geginat; Sergio Abrignani; Massimiliano Pagani
Journal:  Nat Immunol       Date:  2011-06-26       Impact factor: 25.606

7.  Level, phenotype and activation status of CD4+FoxP3+ regulatory T cells in patients chronically infected with human immunodeficiency virus and/or hepatitis C virus.

Authors:  N I Rallón; M López; V Soriano; J García-Samaniego; M Romero; P Labarga; P García-Gasco; J González-Lahoz; J M Benito
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

Review 8.  The discovery of novel experimental therapies for inflammatory arthritis.

Authors:  Charles J Malemud
Journal:  Mediators Inflamm       Date:  2010-03-18       Impact factor: 4.711

9.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

10.  Identification and characterization of IL-10/IFN-gamma-producing effector-like T cells with regulatory function in human blood.

Authors:  Barbara Häringer; Laura Lozza; Bodo Steckel; Jens Geginat
Journal:  J Exp Med       Date:  2009-05-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.